Caplyta Drug Class
Caplyta (lumateperone) is an atypical antipsychotic, also classified as a second-generation or third-generation antipsychotic. 1
Classification Details
Lumateperone is officially described in its FDA labeling as an atypical antipsychotic 1. The drug is present as lumateperone tosylate salt and is approved for oral administration in the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder 1.
Pharmacological Characteristics
Lumateperone represents a mechanistically novel antipsychotic that simultaneously modulates three key neurotransmitter systems:
- Serotonin system: High binding affinity for 5-HT2A receptors (Ki = 0.54 nM) and moderate affinity for serotonin transporters (Ki = 33 nM)
- Dopamine system: Moderate binding affinity for D2 receptors (Ki = 32 nM), with postsynaptic antagonist activity and presynaptic partial agonist properties
- Glutamate system: Indirect modulation of glutamatergic neurotransmission
Third-Generation Classification Debate
Some literature suggests lumateperone may be considered a third-generation antipsychotic alongside aripiprazole, brexpiprazole, and cariprazine, all of which share dopamine-2 receptor partial agonist properties 4. However, the FDA label maintains the traditional "atypical antipsychotic" designation 1.
Key Distinguishing Features from Other Antipsychotics:
- Lower receptor affinity for muscarinic and histaminergic receptors (less than 50% inhibition at 100 nM) 1
- Favorable metabolic profile: Minimal weight gain and cardiometabolic effects compared to other atypicals 4, 5
- Reduced extrapyramidal symptoms: Not significantly associated with EPS commonly seen with other antipsychotics 2, 5
The most clinically relevant classification is atypical (second-generation) antipsychotic, though emerging evidence supports potential reclassification as a third-generation agent based on its unique pharmacodynamic profile and improved tolerability.